Saturday, March 18, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Biodetection

RFI – Next Generation Diagnostic Devices for Biological Threats

by Global Biodefense Staff
January 10, 2014

The Joint Project Management Office for Medical Countermeasure Systems (JPM-MCS), under the Joint Program Executive Office for Chemical and Biological Defense (JPEO-CBD) has issued a Request for Information to support the Joint Product Director for Diagnostics (JPdM Dx) in strategic planning for development of the Next Generation Diagnostics System (NGDS) Increment 2 acquisition.

JPM-MCS is interested in collecting information from companies who are currently in the U.S. domestic healthcare market or are considering a future entry into the market for FDA-cleared diagnostics for human diseases caused by exposure to biological threat agents. JPM-MCS is specifically interesting in information about systems that are complementary to the Increment 1 NGDS sample-to-answer molecular (PCR) diagnostic platform used in forward deployed clinical laboratories, combat support hospitals and ships.

Information gathered will be reviewed as part of a market survey in support of the NGDS Increment 2 acquisition program planned to begin August 2014.

Biological threat types include:

  • Pathogenic bacteria, DNA and RNA
  • Viruses
  • Parasites
  • Fungus
  • Prions
  • Biological toxins (bacterial, plant and animal derived)

Applications for these technologies and systems include: use at small clinical laboratories providing centralized support to fixed site and mobile hospitals less than 200 beds; point of care diagnostics in a CLIA-waived setting; HIPAA-Compliant communications and data processing tools supporting remote data analysis/interpretation of point of care sample analyses; and non-invasive or very low invasive population screening tools to identify people who may benefit from follow-on diagnostic testing. Patients may be tested pre-symptomatically or within 12 to 120 hours of exhibiting symptoms, depending on location of the clinic or laboratory.

The RFI details minimum threshold and ideal system characteristics, such as:

  • Portable, total system weight 0.5 lbs -15 lbs
  • Safe for use with BSL 4 agents (low risk of aerosolizing sample material)
  • Open Architecture supporting 3rd party assay design and development
  • Single Sample Time to Result objective of 5 minutes, no more than 30 minutes
  • Electronically enabled for data archiving and communications
  • Detection of agent specific proteins and biomolecules
  • Detection of disease specific host biomarkers
  • High specificity
  • Supportive of syndrome based diagnostics with endemic diseases
  • Aligned with vaccines and therapeutics in production or development
  • Exiting or emerging FDA regulatory framework to support development and 510k clearance
  • Single use consumable or reusable, adaptable instrument/assay based system
  • FDA cleared for in-vitro diagnostics or sufficiently mature to begin FDA Clinical Trials no later than January 2016

Further details are available under Solicitation Number: Solicitation Number: W911QY-13-RFI-NGDSI2.

Tags: BiomarkersChemical DetectionJPEO-CBRNDMobile ResponsePOC DiagnosticsPrionsRFI

Related Posts

Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
two soldiers are in head-to-toe hazmat suits with respirator masks while tending to a mannikin on a stretcher
CBRNE

Protection from Biothreats: DOD to Modernize Medical Countermeasures Development

January 10, 2023
Killing Anthrax More Quickly with Hot Air Decontamination
CBRNE

Killing Anthrax More Quickly with Hot Air Decontamination

January 4, 2023
New Material Helps Train First Responders on Biothreats
Biodetection

New Material Helps Train First Responders on Biothreats

January 4, 2023
Load More

Latest News

Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

Influenza Proteins Tilt and Wave in ‘Breath-like’ Motions

January 25, 2023
Biodefense Headlines – 24 January 2023

Biodefense Headlines – 24 January 2023

January 24, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC